Brossi Patrícia M, Moreira Juliana J, Machado Thaís S L, Baccarin Raquel Y A
Department of Internal Medicine, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, SP, Brazil.
BMC Vet Res. 2015 Apr 22;11:98. doi: 10.1186/s12917-015-0403-z.
This systematic review aimed to present and critically appraise the available information on the efficacy of platelet rich plasma (PRP) in equine and human orthopedic therapeutics and to verify the influence of study design and methodology on the assumption of PRP's efficacy. We searched Medline, PubMed, Embase, Bireme and Google Scholar without restrictions until July 2013. Randomized trials, human cohort clinical studies or case series with a control group on the use of PRP in tendons, ligaments or articular lesions were included. Equine clinical studies on the same topics were included independently of their design. Experimental studies relevant to the clarification of PRP's effects and mechanisms of action in tissues of interest, conducted in any animal species, were selected.
This review included 123 studies. PRP's beneficial effects were observed in 46.7% of the clinical studies, while the absence of positive effects was observed in 43.3%. Among experimental studies, 73% yielded positive results, and 7.9% yielded negative results. The most frequent flaws in the clinical trials' designs were the lack of a true placebo group, poor product characterization, insufficient blinding, small sampling, short follow-up periods, and adoption of poor outcome measures. The methods employed for PRP preparation and administration and the selected outcome measures varied greatly. Poor study design was a common feature of equine clinical trials. From studies in which PRP had beneficial effects, 67.8% had an overall high risk of bias. From the studies in which PRP failed to exhibit beneficial effects, 67.8% had an overall low risk of bias.
Most experimental studies revealed positive effects of PRP. Although the majority of equine clinical studies yielded positive results, the human clinical trials' results failed to corroborate these findings. In both species, beneficial results were more frequently observed in studies with a high risk of bias. The use of PRP in musculoskeletal lesions, although safe and promising, has still not shown strong evidence in clinical scenarios.
本系统评价旨在展示并批判性地评估有关富血小板血浆(PRP)在马和人类骨科治疗中疗效的现有信息,并验证研究设计和方法对PRP疗效假设的影响。我们检索了Medline、PubMed、Embase、Bireme和谷歌学术,检索无限制直至2013年7月。纳入了关于PRP用于肌腱、韧带或关节损伤的随机试验、人类队列临床研究或有对照组的病例系列。关于相同主题的马临床研究,无论其设计如何均独立纳入。选择了在任何动物物种中进行的、与阐明PRP在感兴趣组织中的作用效果和作用机制相关的实验研究。
本评价纳入了123项研究。在46.7%的临床研究中观察到PRP的有益效果,而在43.3%的研究中未观察到积极效果。在实验研究中,73%产生了阳性结果,7.9%产生了阴性结果。临床试验设计中最常见的缺陷是缺乏真正的安慰剂组、产品特性描述不佳、盲法不足、样本量小、随访期短以及采用的结局指标不佳。PRP制备和给药所采用的方法以及所选的结局指标差异很大。研究设计不佳是马临床试验的一个共同特征。在PRP产生有益效果的研究中,67.8%总体偏倚风险高。在PRP未显示有益效果的研究中,67.8%总体偏倚风险低。
大多数实验研究显示PRP有积极效果。尽管大多数马临床研究产生了阳性结果,但人类临床试验结果未能证实这些发现。在两个物种中,在偏倚风险高的研究中更常观察到有益结果。PRP在肌肉骨骼损伤中的应用虽然安全且有前景,但在临床情况下仍未显示出有力证据。